Delivering COVID-19 vaccine trials at speed: the implementation of a phase IV UK multi-centre randomised controlled trial to determine safety and immunogenicity of COVID-19 vaccines co-administered with seasonal influenza vaccines (ComFluCOV)

被引：0

作者：

Sarah Baos

Rachel Todd

Russell Thirard

Rosie Harris

Jana Kirwan

Katherine Joyce

David Hutton

Adam Finn

Madeleine Clout

Heike Cappel-Porter

Chris A Rogers

Rajeka Lazarus

Lucy Culliford

机构：

[1] University of Bristol,Bristol Trials Centre

[2] University of Bristol,Bristol Vaccine Centre, Schools of Population Health Sciences and of Cellular and Molecular Medicine

[3] University Hospitals Bristol and Weston NHS Foundation Trust,undefined

来源：

Trials | / 25卷

关键词：

COVID-19 vaccine; Influenza vaccine; Randomised controlled trial (RCT); Efficient delivery; Urgent Public Health (UPH);

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[31] Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial
Xia, ShengLi
Zhang, YunTao
Wang, YanXia
Wang, Hui
Yang, YunKai
Gao, George Fu
Tan, WenJie
Wu, GuiZhen
Xu, Miao
Lou, ZhiYong
Huang, WeiJin
Xu, WenBo
Huang, BaoYing
Wang, Wei
Zhang, Wei
Li, Na
Xie, ZhiQiang
Zhu, Xiujuan
Ding, Ling
You, WangYang
Zhao, YuXiu
Zhao, Jun
Huang, LiLi
Shi, XueZhong
Yang, YongLi
Xu, GuangXue
Wang, WenLing
Liu, PeiPei
Ma, Meng
Qiao, YuLing
Zhao, SuHua
Chai, JingJing
Li, QinQin
Fu, Hui
Xu, Ying
Zheng, XiaoTong
Guo, WanShen
Yang, XiaoMing
LANCET INFECTIOUS DISEASES, 2022, 22 (02): : 196 - 208
[32] Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022
Moro, Pedro L.
Zhang, Bicheng
Ennulat, Carol
Harris, Margaret
McVey, Rachel
Woody, Gina
Marquez, Paige
McNeil, Michael M.
Su, John R.
VACCINE, 2023, 41 (11) : 1859 - 1863
[33] Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled phase 2 trial
Zhang, Yuemiao
Ma, Xupu
Yan, Guanghong
Wu, Ying
Chen, Yanli
Zhou, Zumi
Wan, Na
Su, Wei
Liu, Feng-Wei
Dai, Mu-Xian
Yang, Mei
Li, Chunmei
Yu, Xuanjing
Zhang, Liang
Wang, Zhongfang
Zhou, Tai-Cheng
You, Dingyun
Wei, Jia
Zhang, Zijie
Precise CoVaccine study grp, behalf of the Precise-CoVaccine study group
ECLINICALMEDICINE, 2022, 54
[34] Effect of dexamethasone in patients with ARDS and COVID-19 – prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial
Jan Maláska
Jan Stašek
František Duška
Martin Balík
Jan Máca
Jan Hruda
Tomáš Vymazal
Olga Klementová
Jan Zatloukal
Tomáš Gabrhelík
Pavel Novotný
Regina Demlová
Jana Kubátová
Jana Vinklerová
Adam Svobodník
Milan Kratochvíl
Jozef Klučka
Roman Gál
Mervyn Singer
Trials, 22
[35] Tolerability and immunogenicity of an intranasally- administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
Madhavan, Meera
Ritchie, Adam J.
Aboagye, Jeremy
Jenkin, Daniel
Provstgaad-Morys, Samuel
Tarbet, Iona
Woods, Danielle
Davies, Sophie
Baker, Megan
Platt, Abigail
Flaxman, Amy
Smith, Holly
Belij-Rammerstorfer, Sandra
Wilkins, Deidre
Kelly, Elizabeth J.
Villafana, Tonya
Green, Justin A.
Poulton, Ian
Lambe, Teresa
Hill, Adrian V. S.
Ewer, Katie J.
Douglas, Alexander D.
EBIOMEDICINE, 2022, 85
[36] Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial
Oda, Yoshiaki
Kumagai, Yuji
Kanai, Manabu
Iwama, Yasuhiro
Okura, Iori
Minamida, Takeshi
Yagi, Yukihiro
Kurosawa, Toru
Greener, Benjamin
Zhang, Ye
Walson, Judd L.
LANCET INFECTIOUS DISEASES, 2024, 24 (04): : 351 - 360
[37] Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults
Clemens, Sue Ann Costa
Marchevsky, Natalie
Kelly, Sarah
Felle, Sally
Eldawi, Ahmed
Rajasingam, Rupetha
Mahmud, Rawan
Lambe, Teresa
Voysey, Merryn
Gonzalez, Isabela
Milan, Eveline Pipolo
Justino, Maria Cleonice
Bibi, Sagida
Aley, Parvinder
Clemens, Ralf
Pollard, Andrew J. J.
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (02)
[38] Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]
Poh, Xuan Ying
Lee, I. Russel
Lim, Clarissa
Teo, Jefanie
Rao, Suma
Chia, Po Ying
Ong, Sean W. X.
Lee, Tau Hong
Lin, Ray J. H.
Ng, Lisa F. P.
Ren, Ee Chee
Lin, Raymond T. P.
Wang, Lin-Fa
Renia, Laurent
Lye, David Chien
Young, Barnaby E.
TRIALS, 2022, 23 (01)
[39] Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]
Xuan Ying Poh
I. Russel Lee
Clarissa Lim
Jefanie Teo
Suma Rao
Po Ying Chia
Sean W. X. Ong
Tau Hong Lee
Ray J. H. Lin
Lisa F. P. Ng
Ee Chee Ren
Raymond T. P. Lin
Lin-Fa Wang
Laurent Renia
David Chien Lye
Barnaby E. Young
Trials, 23
[40] Design of Randomized, Double-Blind, Controlled, Multi-Centre Phase IIb Trials as Part of the EU-Funded UNISEC Project to Assess the Safety, Immunogenicity and Clinical Efficacy of Cross-Seasonal Universal Influenza Vaccines with or Without Pandemic Influenza Vaccine in Healthy Adults
Liu, Heng
Robinson, Stuart
Ben-Yedidia, Tamar
Caparros-Wanderley, Wilson
Gottlieb, Tanya
Babecoff, Ron
Schmidt, Ed
Huckriede, Anke
Hak, Eelko
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 159 - 159

← 1 2 3 4 5 →